Indication · non-cystic fibrosis bronchiectasis

non-cystic fibrosis bronchiectasis FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 2 non-cystic fibrosis bronchiectasis drugs. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
BRINSUPRI® (brensocatib)INSM—Breakthrough Therapy, Orphan Drug, Priority Review
SAR445399SNY——

Upcoming catalysts

DateDrugCompanyEventIndicationStatusSource
October 2027Month disclosedSAR445399SNYPrimary completionNon-cystic Fibrosis BronchiectasisDelayedClinicalTrials.gov

Past catalysts and decisions

No events in this view.

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 2 and 1.

Questions

What non-cystic fibrosis bronchiectasis drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.